BioPharma Resources

Drug Trial Radar · NCT03178149

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 30, 2019

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD. Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD. This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections. There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317. Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year). During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • ASP7317Drug

    subretinal injection

  • tacrolimusDrug

    oral

  • trimethoprim-sulfamethoxazoleDrug

    oral

  • AcyclovirDrug

    oral

  • NystatinDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES)Time frame: Up to 52 Weeks
  2. Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs)Time frame: Up to 52 Weeks
  3. Safety assessed by Adverse Events (AEs) of special interestTime frame: Up to 52 Weeks
  4. Number of participants with cellular graft failure or rejectionTime frame: Up to 52 Weeks
  5. Incidence of cellular graft failure or rejectionTime frame: Up to 52 Weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Consultants of Arizona LTD, Retinal Research Institute

    Phoenix, Arizona · Withdrawn

  • Jules Stein Eye Institute

    Los Angeles, California · Recruiting

  • Stanford University Byers Eye Institute

    Palo Alto, California · Recruiting

  • Kaiser Permanente Riverside Medical Center

    Riverside, California · Recruiting

  • Retina Consultants of Southwest Florida & National Ophthalmic Research Institute

    Fort Myers, Florida · Withdrawn

  • Retina Specialty Institute

    Pensacola, Florida · Recruiting

  • Emory University Eye Center

    Atlanta, Georgia · Recruiting

  • University Retina and Macula Associates

    Oak Forest, Illinois · Recruiting

  • Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office

    Boston, Massachusetts · Withdrawn

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts · Recruiting

  • University of Michigan Kellog Eye Center

    Ann Arbor, Michigan · Recruiting

  • Deep Blue Retina

    Southaven, Mississippi · Recruiting

  • NJ Retina

    New Brunswick, New Jersey · Withdrawn

  • Casey Eye Institute Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Mid-Atlantic Retina

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Retina, PC

    Nashville, Tennessee · Withdrawn

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

  • Valley Retina Institute

    McAllen, Texas · Completed

  • University of Washington

    Seattle, Washington · Withdrawn

  • Spokane Eye Clinical Research

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.